FDA's acting CDER head Corrigan-Curay heads for the exit amid period of heavy turnover: reports
Only a few days after reports emerged that the director of the FDA's cell and gene therapy office had been abruptly put on administrative leave, a new departure shows that an intense period of leadership turnover at the agency isn't over.
Only a few days after reports emerged that the director of the FDA's cell and gene therapy office had been abruptly put on administrative leave, a new departure shows that an intense period of leadership turnover at the agency isn't over.
